[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.194.83. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

Association of Antiviral Therapy With Risk of Parkinson Disease in Patients With Chronic Hepatitis C Virus Infection

Educational Objective
To determine whether interferon-based antiviral therapy in patients with chronic hepatitis C virus infection is associated with incidence of Parkinson disease.
1 Credit CME
Key Points

Question  Is interferon-based antiviral therapy associated with Parkinson disease incidence in patients with chronic hepatitis C virus infection?

Findings  In this cohort study of 188 152 patients with hepatitis C virus infection, the group treated with antiviral therapy had lower incidence density and risk of developing PD compared with the untreated group.

Meaning  Results of treatment with interferon-based antiviral therapy appeared to support the hypothesis that hepatitis C virus may be a probable risk factor for Parkinson disease.

Abstract

Importance  Epidemiologic evidence suggests that hepatitis C virus (HCV) could be a risk factor for Parkinson disease (PD), but treatment for HCV infection has never been considered in these studies; hence, the association between antiviral therapy and PD incidence has remained unclear. Understanding this association may help in developing strategies to reduce PD occurrence.

Objective  To identify the risk of PD development in patients with HCV infection receiving antiviral treatment and in patients not receiving this treatment.

Design, Setting, and Participants  This cohort study obtained claims data from the Taiwan National Health Insurance Research Database. Adult patients with a new HCV diagnosis with or without hepatitis per International Classification of Diseases, Ninth Revision, Clinical Modification codes and anti-PD medications from January 1, 2003, to December 31, 2013, were selected for inclusion. After excluding participants not eligible for analysis, the remaining patients (n = 188 152) were categorized into treated and untreated groups according to whether they received antiviral therapy. Propensity score matching was performed to balance the covariates across groups for comparison of main outcomes. This study was conducted from July 1, 2017, to December 31, 2017.

Main Outcomes and Measures  Development of PD was the main outcome. A Cox proportional hazards regression model was used to compare the risk of PD, and the hazard ratio (HR) was calculated at 1 year, 3 years, and 5 years after the index date and at the end of the cohort.

Results  A total of 188 152 patients were included in the analysis. An equal number (n = 39 936) and comparable characteristics of participants were retained in the treated group (with 17 970 female [45.0%] and a mean [SD] age of 52.8 [11.4] years) and untreated group (with 17 725 female [44.4%] and a mean [SD] age of 52.5 [12.9] years) after matching. The incidence density of PD was 1.00 (95% CI, 0.85-1.15) in the treated group and 1.39 (95% CI, 1.21-1.57) per 1000 person-years in the untreated group. The advantage of antiviral therapy reached statistical significance at the 5-year follow-up (HR, 0.75; 95% CI, 0.59-0.96), and this advantage continued to increase until the end of follow-up (HR, 0.71; 95% CI, 0.58-0.87).

Conclusions and Relevance  Evidence suggested that the PD incidence was lower in patients with chronic HCV infection who received interferon-based antiviral therapy; this finding may support the hypothesis that HCV could be a risk factor for PD.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Accepted for Publication: March 18, 2019.

Corresponding Authors: Ying-Zu Huang, MD, PhD (yzhuang@cgmh.org.tw), and Rou-Shayn Chen, MD (cerebrum@cgmh.org.tw), Department of Neurology, Chang Gung Memorial Hospital, Linkou Medical Center, No. 5, Fuxing St, Guishan District, Taoyuan, Taiwan 333.

Published Online: June 5, 2019. doi:10.1001/jamaneurol.2019.1368

Author Contributions: Drs W.-Y. Lin and M.-S. Lin contributed equally to the work. Drs Chen and Huang had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: M.-S. Lin, Weng, Fong, Wu, Lu, Huang.

Acquisition, analysis, or interpretation of data: W.-Y. Lin, M.-S. Lin, Yeh, Y.-S. Lin, Chen.

Drafting of the manuscript: W.-Y. Lin, Yeh.

Critical revision of the manuscript for important intellectual content: M.-S. Lin, Weng, Y.-S. Lin, Fong, Wu, Lu, Chen, Huang.

Statistical analysis: W.-Y. Lin, M.-S. Lin, Y.-S. Lin.

Obtained funding: W.-Y. Lin.

Administrative, technical, or material support: W.-Y. Lin, M.-S. Lin, Yeh, Lu.

Supervision: Weng, Wu, Lu, Chen, Huang.

Conflict of Interest Disclosures: None reported.

Funding/Support: This study was funded by grant BMRPD45 from Chang Gung Medical Research Fund of Chang Gung Memorial Hospital, Linkou and by grant CMRPGME0011 from Chang Gung Memorial Hospital, Chiayi.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Meeting Presentation: This paper was presented as a poster at the 5th World Parkinson Congress; June 6, 2019; Kyoto, Japan.

Additional Contributions: We thank Alfred Hsing-Fen Lin, MS, and Zoe Ya-Jhu Syu, MPH, Raising Statistics Consultant Inc, for their statistical assistance. These individuals received compensation and declared no competing interest between the findings of this study and their company.

References
1.
Messina  JP, Humphreys  I, Flaxman  A,  et al.  Global distribution and prevalence of hepatitis C virus genotypes.  Hepatology. 2015;61(1):77-87. doi:10.1002/hep.27259PubMedGoogle ScholarCrossref
2.
Negro  F, Forton  D, Craxì  A, Sulkowski  MS, Feld  JJ, Manns  MP.  Extrahepatic morbidity and mortality of chronic hepatitis C.  Gastroenterology. 2015;149(6):1345-1360. doi:10.1053/j.gastro.2015.08.035PubMedGoogle ScholarCrossref
3.
Gill  K, Ghazinian  H, Manch  R, Gish  R.  Hepatitis C virus as a systemic disease: reaching beyond the liver.  Hepatol Int. 2016;10(3):415-423. doi:10.1007/s12072-015-9684-3PubMedGoogle ScholarCrossref
4.
Olubamwo  OO, Aregbesola  AO, Miettola  J, Kauhanen  J, Tuomainen  TP.  Hepatitis C and risk of coronary atherosclerosis: a systematic review.  Public Health. 2016;138:12-25. doi:10.1016/j.puhe.2016.04.005PubMedGoogle ScholarCrossref
5.
Lin  MS, Guo  SE, Chen  MY,  et al.  The impact of hepatitis C infection on ischemic heart disease via ischemic electrocardiogram.  Am J Med Sci. 2014;347(6):478-484. doi:10.1097/MAJ.0b013e3182a5587dPubMedGoogle ScholarCrossref
6.
Pakpoor  J, Noyce  A, Goldacre  R,  et al.  Viral hepatitis and Parkinson disease: a national record-linkage study.  Neurology. 2017;88(17):1630-1633. doi:10.1212/WNL.0000000000003848PubMedGoogle ScholarCrossref
7.
Wu  WY, Kang  KH, Chen  SL,  et al.  Hepatitis C virus infection: a risk factor for Parkinson’s disease.  J Viral Hepat. 2015;22(10):784-791. doi:10.1111/jvh.12392PubMedGoogle ScholarCrossref
8.
Tsai  HH, Liou  HH, Muo  CH, Lee  CZ, Yen  RF, Kao  CH.  Hepatitis C virus infection as a risk factor for Parkinson disease: a nationwide cohort study.  Neurology. 2016;86(9):840-846. doi:10.1212/WNL.0000000000002307PubMedGoogle ScholarCrossref
9.
Kim  JM, Jang  ES, Ok  K,  et al.  Association between hepatitis C virus infection and Parkinson’s disease.  Mov Disord. 2016;31(10):1584-1585. doi:10.1002/mds.26755PubMedGoogle ScholarCrossref
10.
Golabi  P, Otgonsuren  M, Sayiner  M, Arsalla  A, Gogoll  T, Younossi  ZM.  The prevalence of Parkinson disease among patients with hepatitis C infection.  Ann Hepatol. 2017;16(3):342-348. doi:10.5604/01.3001.0009.8588PubMedGoogle ScholarCrossref
11.
Nahon  P, Bourcier  V, Layese  R,  et al; ANRS CO12 CirVir Group.  Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications.  Gastroenterology. 2017;152(1):142-156.e2. doi:10.1053/j.gastro.2016.09.009PubMedGoogle ScholarCrossref
12.
Hsu  YC, Ho  HJ, Huang  YT,  et al.  Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection.  Gut. 2015;64(3):495-503. doi:10.1136/gutjnl-2014-308163PubMedGoogle ScholarCrossref
13.
Lin  MS, Chung  CM, Lin  WY,  et al.  Antiviral therapy reduces risk of haemorrhagic stroke in patients with HCV infection: a nationwide cohort study.  Antivir Ther. 2018;23(1):43-52. doi:10.3851/IMP3172PubMedGoogle ScholarCrossref
14.
Wangensteen  KJ, Krawitt  EL, Hamill  RW, Boyd  JT.  Parkinsonism in patients with chronic hepatitis C treated with interferons: case reports and review of the literature.  Clin Neuropharmacol. 2016;39(1):1-5. doi:10.1097/WNF.0000000000000120PubMedGoogle ScholarCrossref
15.
Wangensteen  KJ, Krawitt  EL, Hamill  RW, Boyd  JT.  Hepatitis C virus infection: a risk factor for Parkinson’s disease.  J Viral Hepat. 2016;23(7):535. doi:10.1111/jvh.12517PubMedGoogle ScholarCrossref
16.
Boyd  JT, Wangensteen  KJ, Krawitt  EL, Hamill  RW, Kao  CH, Tsai  HH.  Hepatitis C virus infection as a risk factor for Parkinson disease: a nationwide cohort study.  Neurology. 2016;87(3):342. doi:10.1212/01.wnl.0000489939.73359.c3PubMedGoogle ScholarCrossref
17.
Abushouk  AI, El-Husseny  MWA, Magdy  M,  et al.  Evidence for association between hepatitis C virus and Parkinson’s disease.  Neurol Sci. 2017;38(11):1913-1920. doi:10.1007/s10072-017-3077-4PubMedGoogle ScholarCrossref
18.
Wijarnpreecha  K, Chesdachai  S, Jaruvongvanich  V, Ungprasert  P.  Hepatitis C virus infection and risk of Parkinson’s disease: a systematic review and meta-analysis.  Eur J Gastroenterol Hepatol. 2018;30(1):9-13. doi:10.1097/MEG.0000000000000991PubMedGoogle ScholarCrossref
19.
National Health Insurance Administration, Ministry of Health and Welfare. 2014-2015 National Health Insurance annual report. http://www.nhi.gov.tw/Resource/webdata/28140_1_National%20Health%20Insurance%20in%20Taiwan%202014-2015%20(bilingual).pdf. Accessed April 29, 2015.
20.
Yu  ML, Chuang  WL.  Treatment of chronic hepatitis C in Asia: when East meets West.  J Gastroenterol Hepatol. 2009;24(3):336-345. doi:10.1111/j.1440-1746.2009.05789.xPubMedGoogle ScholarCrossref
21.
Omata  M, Kanda  T, Yu  ML,  et al.  APASL consensus statements and management algorithms for hepatitis C virus infection.  Hepatol Int. 2012;6(2):409-435. doi:10.1007/s12072-012-9342-yPubMedGoogle ScholarCrossref
22.
Perico  N, Cattaneo  D, Bikbov  B, Remuzzi  G.  Hepatitis C infection and chronic renal diseases.  Clin J Am Soc Nephrol. 2009;4(1):207-220. doi:10.2215/CJN.03710708PubMedGoogle ScholarCrossref
23.
Younossi  ZM, Stepanova  M, Nader  F, Younossi  Z, Elsheikh  E.  Associations of chronic hepatitis C with metabolic and cardiac outcomes.  Aliment Pharmacol Ther. 2013;37(6):647-652. doi:10.1111/apt.12234PubMedGoogle ScholarCrossref
24.
Ascherio  A, Schwarzschild  MA.  The epidemiology of Parkinson’s disease: risk factors and prevention.  Lancet Neurol. 2016;15(12):1257-1272. doi:10.1016/S1474-4422(16)30230-7PubMedGoogle ScholarCrossref
25.
De Pablo-Fernandez  E, Goldacre  R, Pakpoor  J, Noyce  AJ, Warner  TT.  Association between diabetes and subsequent Parkinson disease: a record-linkage cohort study.  Neurology. 2018;91(2):e139-e142. doi:10.1212/WNL.0000000000005771PubMedGoogle ScholarCrossref
26.
Lin  PY, Chang  SN, Hsiao  TH, Huang  BT, Lin  CH, Yang  PC.  Association between Parkinson disease and risk of cancer in Taiwan.  JAMA Oncol. 2015;1(5):633-640. doi:10.1001/jamaoncol.2015.1752PubMedGoogle ScholarCrossref
27.
Lin  KD, Yang  CY, Lee  MY, Ho  SC, Liu  CK, Shin  SJ.  Statin therapy prevents the onset of Parkinson disease in patients with diabetes.  Ann Neurol. 2016;80(4):532-540. doi:10.1002/ana.24751PubMedGoogle ScholarCrossref
28.
Lin  CH, Lin  JW, Liu  YC, Chang  CH, Wu  RM.  Risk of Parkinson’s disease following anxiety disorders: a nationwide population-based cohort study.  Eur J Neurol. 2015;22(9):1280-1287. doi:10.1111/ene.12740PubMedGoogle ScholarCrossref
29.
Postuma  RB, Aarsland  D, Barone  P,  et al.  Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease.  Mov Disord. 2012;27(5):617-626. doi:10.1002/mds.24996PubMedGoogle ScholarCrossref
30.
Lee  YC, Lin  CH, Wu  RM,  et al.  Discontinuation of statin therapy associates with Parkinson disease: a population-based study.  Neurology. 2013;81(5):410-416. doi:10.1212/WNL.0b013e31829d873cPubMedGoogle ScholarCrossref
31.
Kim  DH, Pieper  CF, Ahmed  A, Colón-Emeric  CS.  Use and interpretation of propensity scores in aging research: a guide for clinical researchers.  J Am Geriatr Soc. 2016;64(10):2065-2073. doi:10.1111/jgs.14253PubMedGoogle ScholarCrossref
32.
Austin  PC.  An introduction to propensity score methods for reducing the effects of confounding in observational studies.  Multivariate Behav Res. 2011;46(3):399-424. doi:10.1080/00273171.2011.568786PubMedGoogle ScholarCrossref
33.
Austin  PC.  Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score.  Am J Epidemiol. 2010;172(9):1092-1097. doi:10.1093/aje/kwq224PubMedGoogle ScholarCrossref
34.
De Virgilio  A, Greco  A, Fabbrini  G,  et al.  Parkinson’s disease: autoimmunity and neuroinflammation.  Autoimmun Rev. 2016;15(10):1005-1011. doi:10.1016/j.autrev.2016.07.022PubMedGoogle ScholarCrossref
35.
Qin  XY, Zhang  SP, Cao  C, Loh  YP, Cheng  Y.  Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis.  JAMA Neurol. 2016;73(11):1316-1324. doi:10.1001/jamaneurol.2016.2742PubMedGoogle ScholarCrossref
36.
Zampino  R, Marrone  A, Restivo  L,  et al.  Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations.  World J Hepatol. 2013;5(10):528-540. doi:10.4254/wjh.v5.i10.528PubMedGoogle ScholarCrossref
37.
Bokemeyer  M, Ding  XQ, Goldbecker  A,  et al.  Evidence for neuroinflammation and neuroprotection in HCV infection-associated encephalopathy.  Gut. 2011;60(3):370-377. doi:10.1136/gut.2010.217976PubMedGoogle ScholarCrossref
38.
Forton  DM, Hamilton  G, Allsop  JM,  et al.  Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study.  J Hepatol. 2008;49(3):316-322. doi:10.1016/j.jhep.2008.03.022PubMedGoogle ScholarCrossref
39.
Weissenborn  K, Ennen  JC, Bokemeyer  M,  et al.  Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment.  Gut. 2006;55(11):1624-1630. doi:10.1136/gut.2005.080267PubMedGoogle ScholarCrossref
40.
Marín-Serrano  E, Rodríguez-Ramos  C, Díaz  F, Martín-Herrera  L, Girón-González  JA.  Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin.  J Viral Hepat. 2006;13(4):230-234. doi:10.1111/j.1365-2893.2005.00679.xPubMedGoogle ScholarCrossref
41.
Fletcher  NF, Wilson  GK, Murray  J,  et al.  Hepatitis C virus infects the endothelial cells of the blood-brain barrier.  Gastroenterology. 2012;142(3):634-643.e6. doi:10.1053/j.gastro.2011.11.028PubMedGoogle ScholarCrossref
42.
Fletcher  NF, McKeating  JA.  Hepatitis C virus and the brain.  J Viral Hepat. 2012;19(5):301-306. doi:10.1111/j.1365-2893.2012.01591.xPubMedGoogle ScholarCrossref
43.
Fishman  SL, Murray  JM, Eng  FJ, Walewski  JL, Morgello  S, Branch  AD.  Molecular and bioinformatic evidence of hepatitis C virus evolution in brain.  J Infect Dis. 2008;197(4):597-607. doi:10.1086/526519PubMedGoogle ScholarCrossref
44.
Radkowski  M, Wilkinson  J, Nowicki  M,  et al.  Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication.  J Virol. 2002;76(2):600-608. doi:10.1128/JVI.76.2.600-608.2002PubMedGoogle ScholarCrossref
45.
Vargas  HE, Laskus  T, Radkowski  M,  et al.  Detection of hepatitis C virus sequences in brain tissue obtained in recurrent hepatitis C after liver transplantation.  Liver Transpl. 2002;8(11):1014-1019. doi:10.1053/jlts.2002.36393PubMedGoogle ScholarCrossref
46.
Pan  W, Banks  WA, Kastin  AJ.  Permeability of the blood-brain and blood-spinal cord barriers to interferons.  J Neuroimmunol. 1997;76(1-2):105-111. doi:10.1016/S0165-5728(97)00034-9PubMedGoogle ScholarCrossref
47.
Goldman  JG, Postuma  R.  Premotor and nonmotor features of Parkinson’s disease.  Curr Opin Neurol. 2014;27(4):434-441. doi:10.1097/WCO.0000000000000112PubMedGoogle ScholarCrossref
48.
Mollenhauer  B, Zhang  J.  Biochemical premotor biomarkers for Parkinson’s disease.  Mov Disord. 2012;27(5):644-650. doi:10.1002/mds.24956PubMedGoogle ScholarCrossref
49.
Reichmann  H.  Premotor diagnosis of Parkinson’s disease.  Neurosci Bull. 2017;33(5):526-534. doi:10.1007/s12264-017-0159-5PubMedGoogle ScholarCrossref
50.
Colombo  G, Lorenzini  L, Zironi  E,  et al.  Brain distribution of ribavirin after intranasal administration.  Antiviral Res. 2011;92(3):408-414. doi:10.1016/j.antiviral.2011.09.012PubMedGoogle ScholarCrossref
51.
Kajihara  M, Montagnese  S, Khanna  P,  et al.  Parkinsonism in patients with chronic hepatitis C treated with interferon-alpha2b: a report of two cases.  Eur J Gastroenterol Hepatol. 2010;22(5):628-631. doi:10.1097/MEG.0b013e32833383e3PubMedGoogle ScholarCrossref
52.
Ritz  B, Rhodes  SL, Qian  L, Schernhammer  E, Olsen  JH, Friis  S.  L-type calcium channel blockers and Parkinson disease in Denmark.  Ann Neurol. 2010;67(5):600-606.PubMedGoogle Scholar
53.
Pasternak  B, Svanström  H, Nielsen  NM, Fugger  L, Melbye  M, Hviid  A.  Use of calcium channel blockers and Parkinson’s disease.  Am J Epidemiol. 2012;175(7):627-635. doi:10.1093/aje/kwr362PubMedGoogle ScholarCrossref
54.
Lee  YC, Lin  CH, Wu  RM, Lin  JW, Chang  CH, Lai  MS.  Antihypertensive agents and risk of Parkinson’s disease: a nationwide cohort study.  PLoS One. 2014;9(6):e98961. doi:10.1371/journal.pone.0098961PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right

Name Your Search

Save Search
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Topics
State Requirements